How Do You Feel After Taking Wegovy: What the Evidence Shows

What the STEP 1 trial tells us about how patients actually felt

The clearest window into the Wegovy experience comes from the STEP 1 trial, 68 weeks, nearly 2,000 adults, semaglutide 2.4mg versus placebo. The published data in the New England Journal of Medicine showed an average body-weight reduction of around 15% in the active group. But the trial also captured how participants felt along the way, and gastrointestinal effects were the dominant early story.

Nausea was reported by a substantial proportion of semaglutide participants, roughly 44% versus 16% in the placebo group. Vomiting, diarrhoea and constipation also occurred more often. Critically, most of these events were mild to moderate in severity, and the majority resolved without stopping treatment. The titration schedule exists precisely for this reason: starting at 0.25mg and stepping up slowly gives your gut time to adapt before the dose that delivers meaningful appetite suppression is reached.

What many participants described was a shift in how eating felt. Food became less compelling. Portion sizes that previously seemed normal now felt excessive. That satiety signal arriving sooner and staying longer is the physiological change driving the results, not a metabolic trick, but a meaningful rewiring of appetite cues. For a fuller picture of the ongoing experience once treatment is established, there is more detail in our dedicated guide.

The first 24–72 hours: what most people notice

The hours immediately after the first injection are when Wegovy's profile is most unfamiliar. Semaglutide reaches peak blood concentration roughly 24–48 hours after a subcutaneous dose, which is why many people feel the most pronounced nausea in that window rather than at the moment of injection. Some people feel nothing particular after the first shot; others feel distinctly queasy.

A question our prescribers hear most weeks is whether nausea means the medicine is not going to suit them. In most cases it does not. The nausea reflects the GLP-1 receptor activity in the gut and brainstem, it is pharmacologically expected, not a sign of an adverse reaction. Staying well hydrated, eating smaller meals, and avoiding rich or fatty foods in the first couple of days after each dose can all reduce its impact. For a detailed account of what happens after the first Wegovy injection specifically, that page walks through it hour by hour.

Fatigue is also common in the first week, a combination of reduced calorie intake and the body's adjustment to altered appetite signalling. It usually lifts as the week progresses. Some people feel a mild headache, particularly if they are eating or drinking less than usual. Keeping fluid intake consistent helps. The NHS semaglutide medicines page lists all commonly reported effects and flags the ones that warrant contacting a clinician.

How feelings change over weeks and months

By weeks three and four on the starter dose, most people find the nausea has reduced significantly. The appetite suppression, conversely, tends to feel more settled and less dramatic, it becomes the new baseline rather than something shocking. Eating habits shift gradually: smaller portions feel natural, skipping a snack does not feel like deprivation, and the pull toward high-calorie foods weakens for many people.

After each dose increase, a mild return of nausea and other GI symptoms is normal. The titration ladder (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg, with the recently approved 7.2mg now available for some patients) means the body adapts incrementally rather than jumping straight to the maintenance dose. Your prescriber determines the pace; never adjust the schedule without clinical guidance.

Psychologically, many people notice a shift in how much mental space food occupies. The constant background thinking about meals, hunger and cravings that many people with obesity describe tends to quieten. This is consistent with GLP-1's effects on brain reward circuits as described in the semaglutide clinical overview. If you are curious about how the broader experience of Wegovy makes you feel overall (beyond the early GI phase) that page covers the psychological and appetite dimensions in more depth.

Side effects that need medical attention and what to watch for

The vast majority of side effects from Wegovy are temporary and manageable. A small number require prompt attention. Severe, persistent stomach pain that radiates to your back (with or without vomiting) should be assessed urgently, as this can be a sign of pancreatitis. The MHRA highlighted acute pancreatitis in a Drug Safety Update for GLP-1 medicines; any suspected case means stopping treatment and seeking same-day medical help.

Gallbladder problems are also reported with semaglutide, upper-right abdominal pain, particularly after eating fatty food, warrants a call to your GP or 111. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) are rare but urgent. If you experience significant vomiting or diarrhoea and cannot keep fluids down, dehydration becomes a real risk and medical advice should be sought.

Less urgently: mood changes, including low mood or unusual thoughts, should be flagged to your prescriber. The evidence base here is still developing, but responsible clinical practice means monitoring psychological wellbeing alongside physical progress. You can report any suspected side effects using the MHRA's Yellow Card scheme. Suspected problems with a specific medicine or supplier can also be raised there. If you have questions about what to do after Wegovy treatment ends or is paused, that guide covers what changes and what to expect.

Treatment with Wegovy is a clinical decision. If you are weighing up whether it suits your situation, start your free consultation with our GPhC-registered prescribers, who review every application personally and the same day it is submitted.